SOURCE: Global Equity Reporter

July 06, 2011 09:00 ET

Reports on NanoViricides, Inc. and China Pharma Holdings, Inc. - New Drugs for New Bugs

BEIJING--(Marketwire - Jul 6, 2011) - Today, announced its research report highlighting NanoViricides, Inc. (OTCBB: NNVC) and China Pharma Holdings, Inc. (NYSE Amex: CPHI). Full report download is available at

While it is thought that the recent health care reform legislation will negatively affect industry profitability over the next few years, it has seen eventual benefits accruing from significant expansion of the market, with new coverage potentially being provided to 32 million currently uninsured Americans. However, firms with well-defined growth prospects and generous dividend yields should sustain as they should perform relatively well over the coming quarters. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology.

Global Equity is reporting on NanoViricides, Inc. as a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a development stage company with several drugs in various stages of early development. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The full report and profile on NanoViricides, Inc. (OTCBB: NNVC) is available here:

Global Equity Reporter features China Pharma Holdings, Inc. because its portfolio includes products for treatment of central nervous system diseases, cerebral and cardio vascular disorders, infectious diseases and respiratory and digestive illnesses. Through Helpson, the Company manufactures and markets generic and branded pharmaceutical products primarily to hospitals and private retailers located throughout the People's Republic of China (PRC). The full report and profile on China Pharma Holdings, Inc. (NYSE Amex: CPHI) is available here:

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research - providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.

Contact Information